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A B S T R A C T S
The purpose of our study was to evaluate initial results following introduction of Hyperthermic Intraperitoneal Che-
motherapy (HIPEC) and Cytoreductive Surgery (CS). Twenty two patients with intraperitoneal malignancy undergone
cytoreductive surgery (CS) and hyperthermic intraoperative chemotherapy (HIPEC) between January of 2007 and Janu-
ary 2010. Nine patients had adenocarcinoma of colorectal origin, 8 patients had ovarian cancer, and 5 had pseudomy-
xoma peritonei. Inclusion criteria were diagnosis of peritoneal carcinomatosis based on intraoperative assessment dur-
ing first operative procedure for intraabdominal malignancy or follow-up diagnostic imaging proof. Excluded were pa-
tients with known malignant proliferation outside abdomen, liver metastasis and ASA score 4 and higher. All patients
with pseudomyxoma peritonei diagnosis are alive, with mean follow-up time 24.8 months (range 15–35). In group of pa-
tients with adenocarcinoma from colorectal origin, 3 died, resulting in mean survival time 7.6 months (range 1–16). In
group of patients with ovarian cancer, 2 died, resulting in mean survival time 13.8 months (range 0–31). Two patients
died in early postoperative period. Most of the patients had some sort of mental disorder. Although HIPEC with CS im-
proves survival, during introduction period higher morbidity and mortality could be expected.
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Introduction
Surgery for peritoneal carcinomatosis in our institu-
tion, prior to introduction of cytoreductive surgery (CS)
and hyperthermic intraperitoneal chemotherapy (HIPEC)
in beginning of 2007, was considered only as palliative
method, dealing with issues like intestinal obstruction
and malignant ascites. Peritoneal carcinomatosis patients
survival is usually less than 6 months1–3. Colorectal can-
cer patients with peritoneal carcinomatosis and pallia-
tive treatment had considerable less mean survival time,
5–7 months4,5, compared to patients treated with cyto-
reductive surgery and hyperthermic intraperitoneal che-
motherapy resulting in 5-year survival rate 20–53%6,7.
Reported median survival for patients with diffuse ma-
lignant peritoneal mesothelioma in high volume tertiary
institution treated without CS and HIPEC was 15 mon-
ths8 compared to 31–75% disease free survival at five
years with CS and HIPEC9,10 and 57% overall survival9.
Even better results are obtained for pseudomyxoma peri-
tonei, resulting in 67–91% overall survival in 5 years11,12
and 44% disease free survival11. Metastatic ovarian can-
cer median survival range from 12–25 months13, and
even in these cases better results are reported14,15. Possi-
bility to perform CS in patients with peritoneal spread
has a potential to remove macroscopic malignant diseases
present intraperitoneally, and combined with HIPEC even
microscopic malignancy up to 2.5mm can be annihilated16.
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Methods
22 patients undergone cytoreductive surgery and hy-
perthermic intraoperative chemotherapy for peritoneal
spread of pseudomyxoma peritonei, colorectal adenocar-
cinoma and ovarian cancer between January of 2007 and
January 2010. Diagnosis were: colorectal origin of ade-
nocarcinoma in 9 patients (primary tumor locations as
follow: rectum (n=5), sigmoid colon (n=1), appendix
(n=3)) of which 4 were recurrent; ovarian cancer in 8 pa-
tients (FIGO IIIc in 6 patients, IIIb in 2), of which 5 were
recurrent; and pseudomyxoma peritonei in 5 patients,
neither one recurrent. Inclusion criteria were diagnosis
of peritoneal carcinomatosis based on intraoperative as-
sessment during first operative procedure for intraabdo-
minal malignancy or follow-up diagnostic imaging proof.
Excluded were patients with known malignant prolifera-
tion outside abdomen, liver metastasis and ASA score 4
and higher. Preoperative assessment and possibility for
complete cytoreduction was based on helical abdominal
CT scan with intravenous contrast. All patients under-
went cytoreductive surgery, based on principles intro-
duced by Sugarbaker17, with no macroscopic residual dis-
ease left, including intestinal resection and lymph node
dissection. Removal of the omentum and involved perito-
neum was carried on in all patients; this mostly involved
paracolic spaces, pelvis, abdominal wall and both subdia-
phragmatic and subhepatic areas. In 4 patients gastre-
ctomy was necessary due tumor involment, and in 13 co-
lonic resections with protective ileostomas. Gallbladder
was removed in 8, spleen in 9 and liver capsule in 8 pa-
tients. Closed technique hyperthermic intraoperative che-
motherapy through 4 abdominal tube drains (2 for in-
flow, and 2 for outflow) using cisplatin (40 m/L) and
doxorubicin (15.25 mg/L) of perfusate (carrier solution
was normal saline in all cases) during 60 min with target
temperature of 42.5°C (3 thermocouples in abdomen
were used) followed in patients with ovarian cancer,
adenocarcinoma patients received oxaliplatin (460 mg/
m2/L) or combination of mitomycin C (35 g/m2/L) and
doxorubicin, and pseudomyxoma patients received mito-
mycin C. Mean flow of perfusate was 600–1000 mL/min,
and volume varied between 4 and 6 L. After HIPEC bilat-
eral thoracic tubes were inserted in all patients as fluid
accumulation in the chest is expected as a result of
peritonectomy and HIPEC. Postoperatively patients re-
sumed chemotherapy with florouracil and leucovorin.
Ovarian cancer patient’s follow-up continued in dedi-
cated gynecological institution. Peritoneal cancer index
(PCI)18 and completeness of cytoreduction scores (CC)
were calculated for all patients following procedure19. Pe-
ri-operative mortality and complications were evaluated.
Results
Twent two patients underwent CRS and HIPEC in
above mentioned period, 19 females and 3 males, mean
age 56 years, (range 29–78, SD=10.98 years). Mortality,
defined as death in the first month after operation, was
4.6% in our group of patients, but 2 patients died in early
postoperative period (14th and 42nd day). First patient
was operated because of intraperitoneal spread from
ovarian cancer, she became hypotensive during proce-
dure and suffered from multiorgan failure in the end.
Second patient had intraperitoneal spread of adenocarci-
noma from appendiceal origin, he developed thrombocy-
topenia and anemia leading to disseminated intravascu-
lar coagulopathy. Others were in good clinical condition
discharged from hospital. Median total operation time
was 347 minutes (range 150–515 min, SD 92 min). Me-
dian total blood loss was 727 mL (range 100–1400 mL,
SD 366 mL). Mean hospital stay in days was 17 (range
9–42 days, SD=7.78). Median follow-up 20 patients were
15.1 months (range 1–35 months). All patients with
pseudomyxoma peritonei are alive, with mean follow-up
time 24.8 months (range 15–35). In group of patients
with adenocarcinoma from colorectal origin, 3 died, re-
sulting in mean survival time 7.6 months (range 1–16).
In group of patients with ovarian cancer, 2 died, resulting
in mean survival time 13.8 months (range 0–31). PCI was
equal or bellow 10 in 13 patients, with median survival
time 17.8 months (range 1–35, SD 9.7), PCI was above 10
in 9 patients with median survival time 7.9 months
(range 0–24, SD 8.9). In group of patients with satisfac-
tory cytoreduction, CC score 0, 14 patients, mean sur-
vival time was 17.5 months (range 0–35, SD 10.4), com-
pared to group with CC score 1 and 2, which mean
survival time was 7.1 months (range 0–21, SD 7.1). Nine
patients out of 20 had postoperative complications (2
who died in early postoperative period are excluded). In 3
patients we had 2 anastomotic leaks, both suffered dehi-
scence of ileorectal anastomosis on 4th day, and one perfo-
ration of small bowel due to technical error obvious on
2nd postoperative day; 4 patients had intraabdominal col-
lection of which 2 required operative evacuation; 1 pa-
tient required blood transfusion and reoperation for ad-
ditional hemostasis; one patient was septic.
Although we didn't evaluate patient mental status
during this operations, it became obvious that most of
the patients did developed some sort of mental disorder,
either anxiety or depression. In discussions experienced
oncologic surgeons mentioned use of opiates as possible
cause during postoperative period. All of our patients had
epidural catheter for pain management, so this couldn't
be case in our group. We intend to monitor this effect in
the future.
Discussion
Peritoneal carcinomatosis is last stage for many in-
traabdominal malignancies. Survival of less than 6 mon-
ths and palliative procedures dealing with intestinal ob-
struction were common for those patients, as were fre-
quent visits to emergency room. Combined treatment of
local heated chemotherapy, which allows exposure to
high drug concentration capable to penetrate tumor bul-
ges less than 2.5 mm thickness, and surgical removal of
larger tumor deposits results in significantly improved
survival in once untreatable patients. Obvious benefits of
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HIPEC are: higher intraabdominal concentration which
helps to overcome chemoresistance decreased systemic
concentrations resulting in decreased side effects20,21. As
described by Sugarbaker et al.22 peritoneal spread for
colorectal cancer occurs first in subdiaphragmatic areas,
pelvis and greater and lesser omentum, latter in subhe-
patic, retrohepatic and paracolic space and Treitz liga-
ment, with finally spread to liver, gallbladder, stomach,
colon and small bowel with adjunct mesentery at last.
Peristalsis, gravity and reabsorption considered main
factors for abdominal spread of low grade mucinous tu-
mors. As seen in many studies, great risks are present in
special patient subgroups. Inability to determine those
patients becomes obvious when one summary the results
of developing team as ours. Those are known facts de-
scribed in learning curve following every new procedure.
Lower morbidity and better overall survival could be
achieved with better patient selection. Two early postop-
erative deaths and rate of 45% of a major peri-operative
complications in presented group of patients is high, and
contributed mostly to newly adopted procedure, but is
expected to come closer to usually reported incidence bel-
low 30%23. Peritoneal cancer index is good prognostic fac-
tor in patients with primary colon cancer with peritoneal
carcinomatosis18 predicting 48 months mean survival
and a 50% survival rate in 5 years for group of patients
with score 10 or bellow. In the other subgroups with
score 11–20 and 20 or above, median survivals is 24
months with 20% in 5 years and 12 months with 0% in 5
years, respectively. Although we didn’t treat only colo-
rectal cancer patients with this method, survival distinc-
tion between patients is obvious for those with PCI 10 or
bellow. The question is how to improve preoperative PCI
assessment mostly based on helical CT imaging to avoid
patients with poor prognosis. Male sex had been de-
scribed as significant factor for morbidity24, conclusion
we are not able to investigate yet on our data. There is no
consensus considering timing for bowel anastomosis, ei-
ther to do it before or after HIPEC25. We did bowel anas-
tomosis before HIPEC, finding this safe and less time
consuming. International workshop on peritoneal sur-
face malignancy held biannually made some consensus
about HIPEC in general during 2006. Isotonic salt solu-
tions and dexterous solutions are considered advisable
for perfusate. Optimal range of temperature for solution
is considered 41–43°C. And drugs for HIPEC used in our
study are considered safe for routine clinical use by ma-
jority of experts26.
Conclusion
CRS with HIPEC significantly improves survival of
patients with peritoneal carcinomatosis and pseudomy-
xoma peritonei. Improvement in survival of ovarian can-
cer patients and colorectal origin adenocarcinoma pa-
tients exist, although not so encouraging as in pseudomy-
xoma group. Earlier referral from other national institu-
tions, with performance of the procedure in earlier phase
of the disease, would improve outcome. During introduc-
tion period higher morbidity and mortality could be ex-
pected, as our institution also encountered 2 deaths in
short postoperative period in first 5 cases.
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HIPERTERMI^KA INTRAPERITONEALNA KEMOTERAPIJA (HIPEC) I CITOREDUKTIVNA
KIRURGIJA (CS) KAO TERAPIJA ZA PERITONEALNI TUMOR: PRELIMINARNI REZULTATI
IZ HRVATSKE
S A @ E T A K
Svrha na{eg istra`ivanja bila je iznijeti na{e po~etne rezultate hipertermijske intraperitonealne kemoterapije
(HIPEC) i citoreduktivne kirurgije (CS). Istra`ivanjem je obuhva}eno 22 bolesnika s karcinozom peritoneuma ili pri-
marnom zlo}udnom tvorbom peritoneuma, u razdoblju od sije~nja 2007. do sije~nja 2010. Devet bolesnika imalo je
adenokarcinom kolona kao primarni tumor, osam bolesnika karcinom jajnika, a pet pseudomiksom peritoneuma. Kri-
teriji za odabir bolesnika pogodnih za ovaj operativni zahvat bili su dijagnoza karcinomatoze peritoneuma za vrijeme
prve operacije zbog maligne bolesti ili dijagnoza pro{irene intraperitonealne maligne bolesti na temelju radiolo{ke obra-
de. Isklju~eni su bolesnici s prijeoperacijski poznatom pro{irenom malignom bolesti van abdomena, s metastazama
jetre, i bolesnici ~iji je anesteziolo{ki rizik za operaciju bio ASA stadij 4 i vi{e. Bolesnici s pseudomiksomom perito-
neuma imali su srednje vrijeme pra}enja 24,8 mjeseci (raspon 15–35), i do kraja pra}enog razdoblja bili su svi `ivi. U
skupini bolesnika s adenokarcinom kolona, troje je umrlo, {to je rezultiralo srednjim vremenom pre`ivljenja 7,6 mjeseci
(raspon 1–16). U skupini bolesnika s karcinom jajnika, dvije bolesnice su umrle, {to je rezultiralo srednjim vremenom
pre`ivljenja 13,8 mjeseci (raspon 0–31). Dvoje bolesnika umrlo je u ranom poslijeoperacijskom razdoblju. Ve}ina bo-
lesnika imala je poslijeoperacijski promjene psiholo{kog statusa odre|enog stupnja, najvi{e u vidu depresivnog sind-
roma. Iako HIPEC sa CS pobolj{ava pre`ivljenje navedenih skupina bolesnika, tijekom razdoblja u~enja ovog novog tipa
operativnog zahvata mo`e se o~ekivati ve}i morbiditet i mortalitet. Ranije upu}ivanje bolesnika u odabrane tercijarne
ustanove vjerojatno bi pridonijelo smanjenju morbiditeta i mortaliteta.
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